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ABSTRACT 
Background & Aims: Genome-wide association studies (GWAS) have identified more than 20 
susceptibility loci for esophageal adenocarcinoma (EA) and Barrett’s esophagus (BE). However, 
variants in these loci account for a small fraction of cases of EA and BE. Genetic factors might 
interact with environmental factors to affect risk of EA and BE. We aimed to identify single 
nucleotide polymorphisms (SNPs) that may modify the associations of body mass index (BMI), 
smoking, and gastroesophageal reflux disease (GERD), with risks of EA and BE. 
 
Methods: We collected data on single BMI measurements, smoking status, and symptoms of 
GERD from 2284 patients with EA, 3104 patients with BE, and 2182 healthy individuals 
(controls) participating in the Barrett’s and Esophageal Adenocarcinoma Consortium GWAS, the 
UK Barrett’s Esophagus Gene Study, and the UK Stomach and Oesophageal Cancer Study. We 
analyzed 993,501 SNPs in DNA samples of all study subjects. We used standard case–control 
logistic regression to test for gene-environment interactions. 
 
Results: For EA, rs13429103 at chromosome 2p25.1, near the RNF144A-LOC339788 gene, 
showed a borderline significant interaction with smoking status (P=2.18×10-7). Ever smoking 
was associated with an almost 12-fold increase in risk of EA among individuals with 
rs13429103-AA genotype (odds ratio=11.82; 95% CI, 4.03–34.67). Three SNPs (rs12465911, 
rs2341926, rs13396805) at chromosome 2q23.3, near the RND3-RBM43 gene, interacted with 
GERD symptoms (P=1.70×10-7, P=1.83×10-7, and P=3.58×10-7, respectively) to affect risk of 
EA. For BE, rs491603 at chromosome 1p34.3, near the EIF2C3 gene, and rs11631094 at 
chromosome 15q14, at the SLC12A6 gene, interacted with BMI (P=4.44×10-7) and pack-years of 
smoking history (P=2.82×10-7), respectively. 
 
Conclusion: The associations of BMI, smoking, and GERD symptoms with risks of EA and BE 
appear to vary with SNPs at chromosomes 1, 2, and 15. Validation of these suggestive 
interactions is warranted. 
 
KEY WORDS: esophageal neoplasm; genetic variants; risk factors; esophagus
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INTRODUCTION 
Over the past four decades, the incidence of esophageal adenocarcinoma (EA) has increased 
markedly in many Western populations. Among white males in the United States the incidence 
has increased almost 10-fold,1 and rates continue to rise by 2% per year.2 EA is a highly fatal 
cancer with a median overall survival of <1 year following diagnosis.3 EAs typically arise on a 
background of a pre-malignant change in the lining of the esophagus known as Barrett’s 
esophagus (BE). Thus, proposals to prevent EA-associated morbidity and mortality have 
suggested focusing on identifying patients with BE and enrolling them in endoscopic 
surveillance programs, or on identifying and modifying risk factors for neoplastic progression.4-6 
 
Epidemiologic studies have identified frequent or persistent symptoms of gastroesophageal 
reflux disease (GERD),7,8 obesity,9 and smoking10, 11 as the principal factors associated with 
increased risks of EA and BE. These three factors together comprise almost 80% of the 
attributable burden of EA.12, 13 Genetic factors also influence risk of EA and BE. Recent genome-
wide association studies (GWAS) and post-GWAS studies have identified more than 20 loci 
significantly associated with risks of EA and BE;14 however, these variants seem to explain only 
a limited proportion of the heritability of these diseases (estimated to be 25% for EA and 35% 
for BE).15 It is possible that environmental risk factors for EA and BE may interact with multiple 
genes through various biological pathways to contribute to disease susceptibility. Given the 
strength of associations with known risk factors for EA and BE (especially when compared with 
most other cancers), and potentially shared biological pathways (e.g., inflammation) underlying 
these risk factors,16 identifying gene-environment interactions may be more plausible in the 
setting of EA and BE. These gene-environment interactions may account for some of the missing 
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heritability of EA and BE.15 However, previous efforts to identify gene-environment interactions 
for EA and BE have predominantly been candidate-based and have involved only small numbers 
of single nucleotide polymorphisms (SNPs).17-19 
 
With the aim of identifying SNPs that may modify the associations of body mass index (BMI), 
smoking and GERD symptoms with risks of EA and BE, we used pooled questionnaire and 
genetic data from several studies to conduct a large scale genome-wide gene-environment 
interaction study of EA and BE.
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METHODS 
Study Population 
We obtained data from 1,512 EA patients, 2,413 BE patients, and 2,185 controls of European 
ancestry from 14 epidemiologic studies conducted in Western Europe, Australia, and North 
America participating in the International Barrett’s and Esophageal Adenocarcinoma Consortium 
(BEACON; http://beacon.tlvnet.net/) GWAS. The design of the BEACON GWAS has been 
described in detail previously.20 Histological confirmation of EA and BE was carried out for all 
the participating studies. The pooled dataset also included an additional 1,003 EA patients and 
882 BE patients from the United Kingdom (UK) Stomach and Oesophageal Cancer Study and 
the UK Barrett’s Esophagus Gene Study, respectively.20 The EA patients in the UK Stomach and 
Oesophageal Cancer Study had International Classification of Diseases coding of malignant 
neoplasm of the esophagus (C15) and pathological diagnosis of adenocarcinoma (M8140-8575). 
The BE patients were identified at endoscopy with confirmed histopathological diagnosis of 
intestinal metaplasia in the UK Barrett's Esophagus Gene Study. Each contributing study was 
performed under institutional review board approval and all participants gave informed consent. 
 
SNP Genotyping  
Genotyping of buffy coat or whole blood DNA from all participants was conducted using the 
Illumina Omni1M Quad platform, in accordance with standard quality control procedures.21 For 
quality control, genotyped SNPs were excluded based on call rate <95%, Hardy-Weinberg 
Equilibrium P-value over controls of <10-4, or minor allele frequency (MAF) ≤2%. After quality 
assurance and quality control, 993,501 SNPs were used for the current analysis. The analysis was 
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restricted to the subset of ethnically homogenous individuals of European ancestry (confirmed in 
GWAS samples using principal components analysis).20  
 
Environmental (“Exposure”) Variables 
Individual-level exposure data for each study participant were harmonized and merged into a 
single de-identified dataset. The data were checked for consistency and completeness and any 
apparent inconsistencies were followed-up with individual study investigators. Depending on the 
study, data from self-reported written questionnaires or in-person interviews were obtained at or 
near the time of cancer diagnosis for EA patients, at or near the time of BE diagnosis for BE 
patients, and at the time of recruitment for controls. BMI was calculated as weight divided by 
square of height (kg/m2). For the analysis we selected the weight from each participant that likely 
reflected usual adult weight (prior to, for example, any disease-related weight loss). For tobacco 
smoking, the exposure variables were smoking status (ever vs. never) and total cigarette smoking 
exposure among ever smokers (pack-years of smoking exposure). Ever cigarette smoking was 
defined as either low threshold exposure (≥100 cigarettes over their whole life) or by asking 
whether they had ever smoked regularly. Pack-years of smoking exposure was derived by 
dividing the average number of cigarettes smoked daily by 20 and multiplying by the total 
number of years smoked. GERD symptoms were defined as the presence of heartburn (i.e., a 
burning or aching pain behind the sternum) or acid reflux (i.e., a sour taste from acid, bile or 
other stomach contents rising up into the mouth).  For analysis, we used the highest reported 
frequency for either GERD symptom. Participants were then categorized as recurrent vs. not 
recurrent based on a frequency of weekly or greater GERD symptoms for ‘recurrent’.7 A total of 
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425 participants with missing values for all three covariates (BMI, smoking history, and history 
of GERD symptoms) were excluded from the analysis. 
 
Statistical Analysis 
We used standard case-control logistic regression to test for gene-environment interactions. SNP 
genotypes were treated as continuous variables and coded as 0, 1, or 2 copies of the minor allele. 
Exposure variables were either continuous (BMI and pack-years of smoking exposure) or 
dichotomous (smoking status and GERD symptoms). We modeled the gene-environment 
interaction by the product of the SNP genotype and the exposure variable, adjusting for age, sex, 
the first four principal components to control for possible population stratification, and the main 
terms of the SNP and the exposure variable. We used model-robust standard errors as suggested 
in Voorman et al.22 to avoid inflated test statistics that can arise due to underestimation of 
variability in gene-environment GWAS. For SNPs from each of the top gene-environment 
interaction hits (i.e., main text, P-value for interaction <5.0×10-7; supplementary material, P-
value for interaction <1.0×10-6) we also performed stratified analyses by genotype to examine 
the modified association of the known risk factor for EA or BE within the specific genotypes. 
Analyses were conducted using R software (The R Foundation for Statistical Computing, 
Vienna, Austria), the GWASTools package,23 and Stata 13.0 (StataCorp LP, College Station, TX, 
USA). 
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RESULTS 
The final study sample included 2,284 EA patients, 3,104 BE patients, and 2,182 controls. 
Characteristics of the study sample are shown in Table 1. On average, BMI was higher among 
EA (mean, 28.4 kg/m2) and BE (28.7 kg/m2) patients than controls (27.0 kg/m2). Similarly, EA 
and BE patients were more likely than controls to be ever smokers (74.8%, 64.8%, and 59.1%, 
respectively) and to report history of recurrent GERD symptoms (46.9%, 52.9%, and 19.4%, 
respectively).  
 
Gene-environment interactions for EA 
For EA, at borderline genome-wide significance, one SNP interacted with smoking status and 
three interacted with recurrent GERD symptoms (P for interactions ranging from 3.58×10-7 to 
1.70×10-7) (Table 2, Figure 1a and 1b). At chromosome 2p25.1, rs13429103 (effect allele 
frequency [EAF]=15.0%) showed interaction with smoking status (RNF144A-LOC339788, P = 
2.18×10-7 for interaction). We also observed borderline statistically significant interactions 
between recurrent GERD symptoms and rs12465911 (P = 1.70×10-7 for interaction), rs2341926 
(P = 1.83×10-7 for interaction) and rs13396805 (P = 3.58×10-7 for interaction) at chromosome 
2q23.3 (RND3-RBM43). These three SNPs are in high linkage disequilibrium (all r2 > 0.9) as 
indicated in Figure 1b. Additional suggestive gene-environment interactions for EA (where 
P<1.0×10-6 for interaction) are shown in Supplementary Table 1.  
 
In analyses stratified by genotype (Table 3), compared to never smoking, ever smoking was 
associated with nearly a 12-fold higher risk of EA among individuals with rs13429103-AA 
genotype (odds ratio [OR]=11.82, 95% confidence interval [CI] 4.03-34.67). In contrast, among 
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individuals with rs13429103-GG genotype, ever smoking conferred only 1.6-fold higher risk of 
EA (OR=1.59, 95% CI 1.36-1.85). Similarly, the risk for EA associated with recurrent GERD 
symptoms was higher in individuals with rs12465911-AA genotype (OR=13.12, 95% CI 6.21-
27.73) than among individuals with rs12465911-GG genotype (OR=2.80, 95% CI 2.29-3.41). 
Additional stratified analyses for risk of EA are shown in Table 3 and Supplementary Table 2. 
 
Gene-environment interactions for BE 
For BE, at chromosome 1p34.3, we observed an interaction between rs491603 (EAF=16.5%) and 
BMI (EIF2C3-LOC100128093, P = 4.44×10-7 for interaction) (Table 2, Figure 1c). At 
chromosome 15p14, rs11631094 (EAF=28.7%) showed interaction with pack-years of smoking 
exposure (SLC12A6, P = 2.82×10-7 for interaction) (Table 2, Figure 1d). Additional suggestive 
significant interactions (where P<1.0×10-6 for interaction) for BE with pack-years of smoking 
exposure at chromosomes 12q23.1, 16p12.3, and 17q12 are presented in Supplementary Table 1. 
 
Stratified analyses by genotype showed that the risk for BE associated with obesity (BMI ≥30 
kg/m2) was elevated by over 200% among individuals with rs491603-AA genotype (vs. BMI 
<25 kg/m2, OR=3.30, 95% CI 1.90-5.73) but only by approximately 50% among individuals 
with rs491603-GG genotype (vs. BMI <25 kg/m2, OR=1.52, 95% CI 1.38-1.67). Additional 
stratified analyses of gene-environment interactions for BE are shown in Table 3 and 
Supplementary Table 2. 
 
Cross-examination of discovered gene-environment interactions 
14 
 
For each SNP in Table 2 and Supplementary Table 1 that had a borderline significant genome-
wide interaction in either EA or BE, we examined the equivalent gene-environment interaction in 
BE and EA, respectively (Supplementary Table 3). For all SNPs discovered in EA, we observed 
nominal levels of significance (P-value for interaction <0.05) and ORs in the same direction but 
somewhat attenuated in BE. For SNPs discovered in BE, only half had P-value for interaction 
<0.05 in EA, although all had similar ORs to those in BE. Although obesity and GERD are 
correlated, none of the SNPs with P-value for interaction <1.0×10-6 with GERD had comparable 
ORs or P-values when testing for interaction with obesity and similarly for the one obesity SNP 
when tested for GERD.
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DISCUSSION 
To our knowledge, this is the first genome-wide gene-environment interaction study of EA and 
its precursor, BE. Although no gene-environment interactions reached genome-wide significance 
(i.e., P<5.0x10-8 for interaction), several borderline significant interactions were indicated 
between SNPs and known risk factors for EA and BE – BMI, smoking and GERD symptoms. 
 
A number of studies have pursued candidate-based gene-environment analyses of EA, and 
reported interactions between BMI, smoking or GERD symptoms and selected SNPs in genes 
related to detoxification, angiogenesis, DNA repair, apoptosis, and extracellular matrix 
degradation.24-31 This body of work helped to establish the notion that the level of disease risk 
associated with GERD symptoms, in particular, may vary according to inherited genetic 
variation. All of these studies, however, were conducted in small samples (<350 cases) and were 
not replicated in independent populations. While direct comparison of our own results and these 
past findings is complicated by less-than-complete overlap of genotyped SNPs between studies, 
we did not find evidence in support of interactions between BMI, smoking or GERD symptoms 
and any assessed variants in previously-implicated genes: GSTM1, GSTT1, VEGF, MGMT, EGF, 
IL1B, PERP, PIK3CA, TNFRSF1A, CASP7, TP53BP1, BCL2, HIF1AN, PDGRFA, VEGFR1, or 
MMP1 (Supplementary Table 4). It remains possible that nominal evidence for some of these 
associations may not have survived stringent correction for multiple comparisons, and larger 
samples are needed for true signals to reach significance. Alternatively, previously reported 
interactions may simply reflect chance findings in small samples since they did not validate in 
our large study population. 
 
16 
 
This study has several strengths. First, the pooled dataset including relatively large numbers of 
cases and controls provided us with a rare opportunity to perform, in parallel, genome-wide 
gene-environment interaction analyses for EA and its precursor lesion, BE. Past candidate-based 
gene-environment interaction studies of EA have focused on small numbers of genes selected 
according to biological plausibility, and collectively these reports sampled only a small fraction 
of the total SNPs presently analyzed (N=993,501). Such preconceived “gene-centric” SNP 
selection methods fail to capture the large fraction of non-coding intergenic variations that have 
been linked to altered risk for these two conditions, and also artificially restricts the “genic” 
search space based on limited mechanistic knowledge, a limitation that is overcome by an 
unbiased comprehensive genome-wide gene-environment interaction assessment. Second, our 
study draws on genetic and epidemiologic data from a recent consortium-based GWAS of 
EA/BE,20 which is the largest of its kind. This sizable study sample afforded greater power to 
detect gene-environment interactions than in any previous study. Third, all genotyping from this 
GWAS was conducted on a single platform and in a single laboratory, and subjected to stringent 
quality control procedures. Most GWAS analyses test only an additive model since an additive 
model has reasonable power to detect both additive and dominant effects and the two models 
yield similar results and many GWAS analyses, including ours, are underpowered to detect 
recessive effects. Nevertheless, for completeness we also tested a dominant model for the 16 
SNPs with P-value for interaction <1.0×10-6 (Table 2 and Supplementary Table 1), and found 
slightly attenuated results of the ORs for some GxE interactions (data not shown). 
 
Our study also has some limitations. First, our ability to detect true gene-environment 
interactions may have been limited by the manner in which the environmental (exposure) 
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variables were measured and harmonized. For example, recall bias is a possibility during 
retrospective reporting of the exposures in the parent case-control studies. However, respondents 
were unaware of their genotype status at the time of the interviews, mitigating the impact of any 
possible recall bias in our interaction analyses. Similarly, while considerable care was taken 
during data harmonization, as described in a series of recent pooled analyses,10, 11 some potential 
for measurement error of the exposures examined is possible. However, given case-control status 
was not considered during this process, any errors from harmonization would be non-differential, 
resulting in attenuation of the resulting ORs. Second, central obesity (e.g., waist-to-hip ratio) has 
been found to be more strongly associated with the risk of BE than BMI; however, as waist and 
hip measurements were not collected in the majority of the included studies we were unable to 
examine for interactions with central obesity. Third, despite the comprehensive nature of the 
genome-wide analysis, we were nonetheless limited to examining common genetic variation 
(MAF>2%) represented on the Illumina Omni1M Quad GWAS platform employed. Further 
large-scale studies based on whole-exome or whole-genome sequencing would be required to 
identify additional gene-environment interactions with rare variants, and more precisely map the 
reported associations. Finally, our study results should be considered as discovery findings, 
worthy of independent replication. None of the interactions studied reached genome-wide 
significance (i.e., P<5.0x10-8 for interaction). This may be because there are truly no gene-
environment interactions or it may be that power was still limited to detect modest or weak 
interactions despite our large sample size. In our analyses of 2,284 EA patients, 3,104 BE 
patients, and 2,182 controls, we were adequately powered to detect interactions with an 
interaction OR in the range of 1.98 to 2.52 for MAF in the observed range (0.11–0.43), assuming 
a main effect of 1.08 for log-additive SNPs, a main effect of 1.90 for binary risk factors, and an α 
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of 5.0×10-8. Given the large worldwide consortia sample of patients participating in this work, 
few additional studies of EA and BE patients are currently available and have data for 
replication, thus such work may require additional time for study patients to accrue. 
 
In conclusion, our report describes the first genome-wide gene-environment interaction analysis 
for EA and BE. These findings provide evidence that the magnitude of disease risk associated 
with BMI, smoking, and GERD symptoms may differ according to germline genetics, and 
suggest the potential utility of combing epidemiologic exposure data with selected genotyping 
for comprehensive risk assessment in patients susceptible to EA/BE. Pending validation of the 
observed interactions in independent study populations, further analyses will be required to 
investigate the biological basis for differential disease risk associated with the risk factors 
investigated in the presence of these variants. 
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Figure Legend 
 
Figure 1. Regional association plots for genotyped SNPs showing P-values for interaction for 
smoking status (a) and recurrent GERD symptoms (b) in esophageal adenocarcinoma and BMI 
(c) and pack-years of smoking exposure (d) in Barrett’s esophagus. The SNPs in Table 2 are 
shown as a solid purple diamond, except in (b) where rs2341926 and rs13396805 are shown as 
circles near rs12465911. The color scheme indicates linkage disequilibrium between the SNP 
shown with a solid purple diamond and other SNPs in the region using the r2 value calculated 
from the 1000 genomes project. The y-axis is the −log10 interaction p-value computed from 
5,388 cases (3,104 Barrett’s esophagus, 2,284 esophageal adenocarcinoma) and 2,182 controls. 
The recombination rate from CEU HapMap data (right side y axis) is shown in light blue. (a) 
Chromosome 2p25.1. (b) Chromosome 2q23.3 region. (c) Chromosome 1p34.3 region. (d) 
Chromosome 15q14 region. 
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Table 1 Characteristics of the study population 
 
Characteristics Controls  EA  
Controls vs. 
EA  BE 
Controls vs. 
BE   
n=2182 n=2284 P-value* n=3104 P-value* 
Age in years, Mean (SD) 61.7 (11.1) 65.1 (10.3) <0.001 62.9 (12.1) <0.001 
Sex   <0.001  0.008 
Male 1715 (78.6) 1990 (87.1)  2343 (75.5)  
Female 467 (21.4) 294 (12.9)  761 (24.5)  
Body mass index (kg/m2)   <0.001  <0.001 
Mean (SD) 27.0 (4.7) 28.4 (5.2)  28.7 (5.1)  
<25 786 (36.3) 245 (24.6)  608 (20.7)  
25-29.99 944 (43.5) 455 (45.8)  1191 (42.8)  
≥30 436 (20.2) 296 (29.6)  935 (36.5)  
Missing 16 1288  370  
Smoking status   <0.001  <0.001 
Never 888 (40.9) 568 (25.2)  1081 (35.2)  
Ever 1282 (59.1) 1686 (74.8)  1994 (64.8)  
Missing 12 30  29  
Cumulative smoking history (pack-
years)†   0.43  0.001 
Mean (SD) 32.8 (27.9) 33.6 (26.4)  29.4 (24.8)  
Recurrent GERD symptoms   <0.001  <0.001 
No 1446 (80.6) 965 (53.1)  1058 (47.1)  
Yes 348 (19.4) 854 (46.9)  1186 (52.9)  
Missing 388 465  860  
BE, Barrett’s esophagus; EA, esophageal adenocarcinoma; GERD, gastroesophageal reflux disease; SD, standard 
deviation.  
*P-value from Chi-square tests for categorical variables and Student’s t-test for continuous variables. Missing categories 
were excluded from comparison tests. †Among ever smokers. 
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Table 2 Gene-environment interactions with esophageal adenocarcinoma or Barrett’s esophagus with a P-value for interaction 
<5.0x10-7 
 
Outcome Exposure SNP Chr Position Gene Effect/ Other EAF OR P 
EA          
 Smoking status rs13429103 2p25.1 7517231 RNF144A-LOC339788 A/G 0.15 2.04 2.18×10-7 
 Recurrent GERD symptoms rs12465911 2q23.3 151785742 RND3-RBM43 A/G 0.26 2.03 1.70×10-7 
 Recurrent GERD symptoms rs2341926 2q23.3 151783928 RND3-RBM43 C/T 0.26 2.02 1.83×10-7 
 Recurrent GERD symptoms rs13396805 2q23.3 151821512 RND3-RBM43 A/G 0.26 1.99 3.58×10-7 
          
BE          
 BMI (continuous, kg/m2) rs491603 1p34.3 36532316 EIF2C3-LOC100128093 A/G 0.16 1.08 4.44×10-7 
 Pack-years of smoking rs11631094 15q14 34624438 SLC12A6 A/C 0.29 0.99 2.82×10-7 
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, 
gastroesophageal reflux disease; OR, odds ratio; SNP, single nucleotide polymorphism.  
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Table 3 Risk of esophageal adenocarcinoma and Barrett’s esophagus in association with obesity, smoking history and recurrent GERD 
symptoms, stratified by genotype for SNPs in Table 2 
 
Outcome Environmental exposure SNP Genotype Cases/Controls OR 95% CI P* 
EA        
 Ever smoker vs. Never smoker (ref) rs13429103 GG 1,617/1,572 1.59 1.36-1.85 <0.001 
   GA 589/554 2.91 2.23-3.81 <0.001 
   AA 48/44 11.82 4.03-34.67 <0.001 
        
 Recurrent GERD symptoms vs. Non-recurrent GERD symptoms (ref) rs12465911 GG 1,206/1,196 2.80 2.29-3.41 <0.001 
   GA 885/823 5.32 4.10-6.90 <0.001 
   AA 163/151 13.12 6.21-27.73 <0.001 
        
 Recurrent GERD symptoms vs. Non-recurrent GERD symptoms (ref) rs2341926 TT 975/985 2.80 2.30-3.42 <0.001 
   TC 724/681 5.30 4.08-6.88 <0.001 
   CC 120/128 13.12 6.21-27.73 <0.001 
        
 Recurrent GERD symptoms vs. Non-recurrent GERD symptoms (ref) rs13396805 GG 998/1,005 2.85 2.34-3.48 <0.001 
   GA 701/662 5.23 4.02-6.81 <0.001 
   AA 120/127 12.73 6.12-26.49 <0.001 
BE        
 BMI ≥30 kg/m2 vs. BMI <25 kg/m2 (ref)  rs491603 GG 1,306/1,137 1.52 1.38-1.67 <0.001 
   GA 438/518 2.11 1.80-2.47 <0.001 
   AA 42/64 3.30 1.90-5.73 <0.001 
        
 ≥15 pack-years vs. <15 pack-years (ref) rs11631094 CC 729/618 1.02 0.81-1.30 0.846 
   CA 555/540 0.65 0.50-0.84 0.001 
   AA 115/106 0.52 0.28-0.95 0.033 
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BE, Barrett’s esophagus; BMI, body mass index; CI, confidence interval; EA, esophageal adenocarcinoma; GERD, gastroesophageal 
reflux disease; OR, odds ratio; SNP = single nucleotide polymorphism. 
*P values from logistic regression analysis adjusted for age and sex. 
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Supplementary Table 1 Gene-environment interactions with esophageal adenocarcinoma or Barrett’s esophagus with a P-value for 
interaction <1.0x10-6 
 
Outcome Exposure SNP Chr Position Gene Effect/ Other EAF OR P 
EA          
 Smoking status rs2434584 5q11.2 57566073 ACTBL2-PLK2 C/T 0.08 2.52 7.44×10-7 
 Smoking status rs40210 5q11.2 57619964 ACTBL2-PLK2 A/G 0.08 2.46 8.82×10-7 
 Pack-years of smoking rs17002540 Xq27.1 139946061 CDR1-SPANXB2 T/C 0.19 0.99 
5.92×10-
7 
 Recurrent GERD symptoms rs2971030 7p21.3 10006341 LOC340268 G/A 0.42 1.77 6.02×10-7 
 Recurrent GERD symptoms rs7141987 14q32.31 101492224 SNORD114-31-LOC100130814 G/A 0.42 1.77 
7.11×10-
7 
 Recurrent GERD symptoms rs2971028 7p21.3 10007255 LOC340268 A/G 0.40 1.76 8.56×10-7 
          
BE          
 Pack-years of smoking rs9668109 12q23.1 99011272 IKIP A/G 0.09 0.98 6.31×10-7 
 Pack-years of smoking rs1548445 16p12.3 19691583 C16orf62 G/A 0.06 1.02 8.21×10-7 
 Pack-years of smoking rs2671828 17q12 33731764 SLFN11-LOC729839 A/G 0.43 0.99 
9.54×10-
7 
 Pack-years of smoking rs10507102 12q23.1 98990871 SLC25A3 A/G 0.09 0.98 9.91×10-7 
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, 
gastroesophageal reflux disease; OR, odds ratio; SNP, single nucleotide polymorphism. 
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